ReviewNature reviews. Drug discovery2011
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.
Review in Nature reviews. Drug discovery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 2 syntheses or guidelines pooled it, 291 citations in OpenAlex.
- Comparative efficacy and safety of anticoagulant therapies in coronary artery disease: a network meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2025Pooled it
- 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.The Journal of thoracic and cardiovascular surgery · 2014Guideline
- XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.Vascular health and risk management · 2014Trial
- Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.Clinical pharmacokinetics · 2014Trial
- Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012Trial
- Recent advances in progress of natural anticoagulant active substances.Journal of natural medicines · 2026Review
- Trends and Hot Spots in Research Related to Rivaroxaban: Bibliometric Analysis.Clinics and practice · 2025Article
- Functional characterization of a common XIa inhibitory Kunitz-domain Shp4 from nine schistosoma secreted proteins with diverse C-terminal fragments.PLoS neglected tropical diseases · 2025Article
- Reversible High-Affinity Binding of Coagulation Factor Xa to Zeolites Induces Accelerated Blood Coagulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Review
- Improvement in XIa Selectivity of Snake Venom Peptide Analogue BF9-N17K Using P2' Amino Acid Replacements.Toxins · 2025Article
- Indications and outcomes of rivaroxaban use in cats.Frontiers in veterinary science · 2025Article
- The Future of Medicine: AI and ML Driven Drug Discovery Advancements.Current topics in medicinal chemistry · 2025Review
- Comparative genomics of three non-hematophagous leeches (Frontiers in genetics · 2025Article
- Effects of DOACs on Mouse Melanoma Metastasis and the Inhibitory Mechanism of Edoxaban, a Factor Xa-Specific DOAC.TH open : companion journal to thrombosis and haemostasis · 2025Article
- Breaking boundaries: exploring recent advances in anticoagulation and thrombosis management: a comprehensive review.Annals of medicine and surgery (2012) · 2024Review
- ABCG2 polymorphism and rivaroxaban pharmacokinetics in healthy individuals after a single dose.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Article
- Inhibition of Factor XI: A New Era in the Treatment of Venous Thromboembolism in Cancer Patients?International journal of molecular sciences · 2023Review
- Article
- Edoxaban, a Factor Xa-Specific Direct Oral Anticoagulant, Significantly Suppresses Tumor Growth in Colorectal Cancer Colon26-Inoculated BALB/c Mice.TH open : companion journal to thrombosis and haemostasis · 2023Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The activated serine protease factor Xa is a promising target for new anticoagulants. After studies on naturally occurring factor Xa inhibitors indicated that such agents could be effective and safe, research focused on small-molecule direct inhibitors of factor Xa that might address the major clinical need for improved oral anticoagulants. In 2008, rivaroxaban (Xarelto; Bayer HealthCare) became the first such compound to be approved for clinical use. This article presents the history of rivaroxaban's development, from the structure-activity relationship studies that led to its discovery to the preclinical and clinical studies, and also provides a brief overview of other oral anticoagulants in advanced clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.